|Mr. David M. Stack||Chairman and Chief Exec. Officer||1.17M||4.52M||67|
|Mr. Charles A. Reinhart III||Chief Financial Officer||386.83k||N/A||56|
|Ms. Kristen Williams J.D.||Chief Admin. Officer, Gen. Counsel and Sec.||552.13k||N/A||43|
|Dr. Scott Braunstein M.D.||Sr. VP of Strategy & Corp. Devel.||554.4k||N/A||54|
|Mr. Robert J. Weiland||Chief Commercial Officer||454.46k||N/A||57|
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The companys lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its development pipeline comprises DepoTranexamic Acid, a long-acting local antifibrinolytic agent, which is in Phase II clinical development for the treatment or prevention of excessive blood loss during surgery by preventing the breakdown of a clot; and DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Pacira Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 9. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 7; Compensation: 10.